Artiva Biotherapeutics Shares Fall 31% After AlloNK Development Plan
Artiva Biotherapeutics shares fell 31% after the company announced a plan to end AlloNK development; an analyst also downgraded the shares.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.